140 related articles for article (PubMed ID: 1504057)
21. Tumor specific cytolysis by tumor infiltrating lymphocytes in breast cancer.
Baxevanis CN; Dedoussis GV; Papadopoulos NG; Missitzis I; Stathopoulos GP; Papamichail M
Cancer; 1994 Aug; 74(4):1275-82. PubMed ID: 7914469
[TBL] [Abstract][Full Text] [Related]
22. Effects of cytokines on in vitro growth of tumor-infiltrating lymphocytes obtained from human primary and metastatic liver tumors.
Shimizu Y; Iwatsuki S; Herberman RB; Whiteside TL
Cancer Immunol Immunother; 1991; 32(5):280-8. PubMed ID: 1847844
[TBL] [Abstract][Full Text] [Related]
23. [Adoptive immunotherapy and metastasized cancer of the kidney. Regulator effects of interleukin-4 on tumor infiltrating lymphocytes (TIL)].
Peyret C; Bochner B; Lee TY; Tso CL; Dekernion JB; Belldegrun A
Chirurgie; 1991; 117(9):700-9. PubMed ID: 1843670
[TBL] [Abstract][Full Text] [Related]
24. Lymphocytes infiltrating human ovarian tumors. I. Role of Leu-19 (NKH1)-positive recombinant IL-2-activated cultures of lymphocytes infiltrating human ovarian tumors.
Heo DS; Whiteside TL; Kanbour A; Herberman RB
J Immunol; 1988 Jun; 140(11):4042-9. PubMed ID: 3286766
[TBL] [Abstract][Full Text] [Related]
25. Phenotypic and functional analysis of lymphocytes infiltrating paediatric tumours, with a characterization of the tumour phenotype.
Rivoltini L; Arienti F; Orazi A; Cefalo G; Gasparini M; Gambacorti-Passerini C; Fossati-Bellani F; Parmiani G
Cancer Immunol Immunother; 1992; 34(4):241-51. PubMed ID: 1311218
[TBL] [Abstract][Full Text] [Related]
26. [Antitumor effector cells in recombinant IL-2 activated tumor infiltrating lymphocytes from human solid cancers].
Ishii S; Shiiba K; Ebina N; Matsuno S
Nihon Geka Gakkai Zasshi; 1993 Mar; 94(3):213-24. PubMed ID: 7686244
[TBL] [Abstract][Full Text] [Related]
27. Characterization of the CD4+ and CD8+ tumor infiltrating lymphocytes propagated with bispecific monoclonal antibodies.
Wong JT; Pinto CE; Gifford JD; Kurnick JT; Kradin RL
J Immunol; 1989 Nov; 143(10):3404-11. PubMed ID: 2509557
[TBL] [Abstract][Full Text] [Related]
28. In search of specific cytotoxic T lymphocytes infiltrating or accompanying human ovarian carcinoma.
Apiranthitou-Drogari M; Paganin C; Bernasconi S; Losa G; Maneo A; Colombo N; Mantovani A; Allavena P
Cancer Immunol Immunother; 1992; 35(4):289-95. PubMed ID: 1387344
[TBL] [Abstract][Full Text] [Related]
29. Adherent cell depletion promotes the expansion of renal cell carcinoma infiltrating T cells with optimal characteristics for adoptive transfer.
Braun MW; Abdelhakim H; Li M; Hyter S; Pessetto Z; Koestler DC; Pathak HB; Dunavin N; Godwin AK
J Immunother Cancer; 2020 Oct; 8(2):. PubMed ID: 33037114
[TBL] [Abstract][Full Text] [Related]
30. The effects of interleukin-6 on tumor-infiltrating lymphocytes derived from human renal cell cancer.
Lee TY; Koo AS; Peyret C; Shimabukuro T; Dekernion JB; Belldegrun A
J Urol; 1991 Mar; 145(3):663-7. PubMed ID: 1997727
[TBL] [Abstract][Full Text] [Related]
31. Phenotype, cytokine production and cytolytic capacity of fresh (uncultured) tumour-infiltrating T lymphocytes in human renal cell carcinoma.
Van den Hove LE; Van Gool SW; Van Poppel H; Baert L; Coorevits L; Van Damme B; Ceuppens JL
Clin Exp Immunol; 1997 Sep; 109(3):501-9. PubMed ID: 9328129
[TBL] [Abstract][Full Text] [Related]
32. Characterization of fresh (uncultured) tumour-infiltrating lymphocytes (TIL) and TIL-derived T cell lines from patients with renal cell carcinoma.
Mitropoulos D; Kooi S; Rodriguez-Villanueva J; Platsoucas CD
Clin Exp Immunol; 1994 Aug; 97(2):321-7. PubMed ID: 8050183
[TBL] [Abstract][Full Text] [Related]
33. Human accessory cells activate fresh, normal, tumor-distant T lymphocytes but not tumor-infiltrating T lymphocytes to lyse autologous tumor cells in a primary cytotoxic T lymphocyte assay in renal cell carcinoma.
Kramer G; Steiner GE; Paiha S; Handisurya A; Djavan B; Mallone R; Marberger M
Eur Urol; 2001 Oct; 40(4):427-33. PubMed ID: 11713398
[TBL] [Abstract][Full Text] [Related]
34. Lymphocytes infiltrating ovarian malignant ascites: modulation of IL-2-induced proliferation by IL-4 and of selective increase in CD8+ T cells by TNF-alpha.
Ioannides CG; Rashed S; Fisk B; Fan D; Itoh K; Freedman RS
Lymphokine Cytokine Res; 1991 Aug; 10(4):307-15. PubMed ID: 1932375
[TBL] [Abstract][Full Text] [Related]
35. Characterization of tumor-infiltrating lymphocytes derived from human tumors for use as adoptive immunotherapy of cancer.
Schiltz PM; Beutel LD; Nayak SK; Dillman RO
J Immunother; 1997 Sep; 20(5):377-86. PubMed ID: 9336745
[TBL] [Abstract][Full Text] [Related]
36. Growth and autologous tumor lysis by tumor-infiltrating lymphocytes from metastatic melanoma expanded in interleukin-2 or interleukin-2 plus interleukin-4.
Lindgren CG; Thompson JA; Higuchi CM; Fefer A
J Immunother Emphasis Tumor Immunol; 1993 Nov; 14(4):322-8. PubMed ID: 8280715
[TBL] [Abstract][Full Text] [Related]
37. In vitro enhanced cytotoxicity of tumor-infiltrating lymphocytes transfected with tumor necrosis factor-related apoptosis-inducing ligand and/or interleukin-2 gene in human renal cell carcinoma.
Tian JQ; Wang ZP; Rodriguez R; Fu JS; Lu JZ; Ma BL
Urology; 2006 May; 67(5):1093-8. PubMed ID: 16635513
[TBL] [Abstract][Full Text] [Related]
38. Characterization of human tumor-infiltrating lymphocytes expanded in hollow-fiber bioreactors for immunotherapy of cancer.
Malone CC; Schiltz PM; Mackintosh AD; Beutel LD; Heinemann FS; Dillman RO
Cancer Biother Radiopharm; 2001 Oct; 16(5):381-90. PubMed ID: 11776755
[TBL] [Abstract][Full Text] [Related]
39. Specific antitumor activity of tumor-infiltrating lymphocytes expanded first in a culture with both anti-CD3 monoclonal antibody and activated B cells and then in a culture with interleukin-2.
Tamada K; Harada M; Okamoto T; Takenoyama M; Ito O; Matsuzaki G; Nomoto K
Cancer Immunol Immunother; 1995 Dec; 41(6):339-47. PubMed ID: 8635191
[TBL] [Abstract][Full Text] [Related]
40. Interleukin 7 enhances the proliferation and effector function of tumor-infiltrating lymphocytes from renal-cell carcinoma.
Sica D; Rayman P; Stanley J; Edinger M; Tubbs RR; Klein E; Bukowski R; Finke JH
Int J Cancer; 1993 Apr; 53(6):941-7. PubMed ID: 8473051
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
